Press Release Articles 2026 2025 2024 Past-2023 Interim Analysis (Cross‑Reactivity) of Phase 1 Clinical Study in Europe on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)2026-2-26 The Logo and Abbreviation will be changed for the 10th Anniversary from April!2025-1-17 CD4+ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy | National Institutes of Biomedical Innovation, Health and Nutrition2024-9-17 Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate2024-5-14
